Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management
- First Online:
- Cite this article as:
- Rosty, C., Hewett, D.G., Brown, I.S. et al. J Gastroenterol (2013) 48: 287. doi:10.1007/s00535-012-0720-y
- 3.3k Downloads
Approximately 30 % of colorectal carcinomas develop via the serrated neoplasia pathway characterized by widespread DNA methylation and frequent BRAF mutation. Serrated polyps represent a heterogeneous group of polyps which are the precursor lesions to serrated pathway colorectal carcinomas. The histological classification of serrated polyps has evolved over the last two decades to distinguish three separate entities: hyperplastic polyp, sessile serrated adenoma (SSA), and traditional serrated adenoma (TSA). The malignant potential of SSAs and TSAs has been clearly demonstrated. SSAs are more challenging to detect by colonoscopy and are likely to account for some interval carcinomas of the proximal colon. Serrated polyposis syndrome is now widely recognized as conferring a high risk of colorectal carcinoma although its cause remains elusive. The current understanding of the actual malignant potential of each serrated polyp subtype is still limited due to the lack of large-scale prospective studies. Patient management guidelines have been recently updated although high-level evidence to support them is still required.
KeywordsSerrated polypsColorectal neoplasiaColonoscopyHistologyMolecular pathologyPatient management
Colorectal carcinoma (CRC) is one of the most common cancers worldwide. Virtually all CRCs originate from a precursor benign polyp, which makes this cancer potentially preventable by appropriate screening colonoscopy programs in patients at increased risk. Until approximately 1990, colorectal polyps were classified into two groups: adenomatous polyps (conventional adenomas) with a well-recognized potential for malignant transformation and hyperplastic (or ‘metaplastic’) polyps thought to have no risk of malignant transformation. While conventional adenomas are still considered to represent the precursor lesions of the majority of CRC, the group of polyps previously called ‘hyperplastic polyps’ has now been divided in various subtypes with respect to their morphologic appearance, molecular alterations, and risk of malignant transformation.
Over the last 20 years, our understanding of CRC pathogenesis has evolved from the concept of a single disease progressing through a sequence of morphologic and genetic alterations  to the concept of molecular heterogeneity and tumor uniqueness . CRC is currently classified into subgroups of tumors which share similar molecular alterations in correlation with morphologic appearance and clinical features [3, 4]. Such classifications can become more and more complex as the number of classifiers increases to reach a complete set of characteristics that underlies the concept of a unique tumor arising in a unique individual. Therefore a meaningful classification should retain parameters with clinical consequences for patient management such as prevention, treatment, and surveillance. The nature of the precursor polyp is an essential classifier of CRC because each tumor is thought to develop from a unique benign polyp with its own set of morphologic and molecular characteristics. The heterogeneity of CRC translates to a certain extent into the multiplicity of precursor polyp subtypes that we have only recently started to understand. Conventional adenomas are the precursor lesions to CRCs developing via the traditional adenoma–carcinoma pathway characterized by chromosomal instability (except in patients with Lynch syndrome). Serrated polyps are the precursors of CRCs developing through the serrated neoplasia pathway characterized by BRAF mutation, CpG island methylator phenotype (CIMP), with or without microsatellite instability (MSI).
Serrated polyps represent a group of polyps with various recently recognized subtypes associated with different colonoscopic appearance, histology, molecular alteration, and risk of progression to malignancy: hyperplastic polyp (HP), sessile serrated adenoma (SSA), and traditional serrated adenoma (TSA). In this review, we will present our current knowledge about serrated polyps and the challenges that pathologists, gastroenterologists, and molecular biologists still face in understanding the clinical significance of these lesions for the patients.
Prevalence and risk factors for serrated polyps
Prevalence of sessile serrated adenomas from different population studies
Number of patients
Prevalence per patient (%)
Spring et al. 2006 
Clinical indications for colonoscopy
Single expert using standard definition chromoendoscopy
Single expert pathologist
Gurudu et al. 2010 
Clinical indications for colonoscopy
Standard care using standard definition white light colonoscopy
? Standard care
Hetzel et al. 2010 
Average risk screening
Standard care using white light colonoscopy
The risk factors for SSAs and TSAs are still being defined. There is strong evidence from case control studies that smoking is associated with an increased risk of SSAs with an odds ratio of approximately 7 [9, 10]. This is supported by data showing an association between smoking and CRCs which are CIMP-high (high level of CIMP) and harbor BRAF mutation . There is also strong evidence that there is a genetic predisposition to serrated neoplasia and that the genes involved may be more common in Caucasians [12, 13]. The genetic predisposition may be a continuum involving a number of genes, each of moderate effect, which interact with environmental factors such as smoking. At one end of the spectrum may be serrated polyposis whilst other individuals may have a few SSAs in the proximal colon and an increased lifetime risk of CIMP-high BRAF-mutated CRC [14, 15]. A recent population-based study showed an increased cancer predisposition in family members of patients with BRAF-mutated CRC . There is likely to be overlap between the environmental and genetic risk factors for SSAs and conventional adenomas as individuals with SSAs are more likely to also have conventional adenomas as well as multiple serrated polyps [17–19].
Definition and histological classification of serrated polyps
In contrast to conventional adenomas, serrated polyps have in common a ‘saw-tooth’ appearance of the colonic crypts. This pattern is thought to result from decreased apoptosis and increased senescence of epithelial cells along the crypts . According to the latest World Health Organization (WHO) classification published in 2010 , serrated polyps are now categorized into three main subtypes: hyperplastic polyps, sessile serrated adenoma/polyps without or with cytological dysplasia, and traditional serrated adenomas. The terms sessile serrated adenoma and sessile serrated polyp are both synonyms and acceptable in diagnostic use. An easy conceptual way to define and differentiate these subgroups is based on differences in location of the proliferation zones within the serrated crypts in each subgroup [22, 23]. In HP, the expanded proliferation zone is located at the base of the crypts (like in normal crypts) and cells mature towards the surface symmetrically. In SSA, the proliferation zone is shifted from the base to the side of the crypts resulting in maturation of epithelial cells towards the surface and the base, leading to crypt base dilatation. In TSA, the proliferation zone is represented by multiple small ectopic crypt formations from the side of the original crypts and along the newly formed villous projections of the polyp .
Main characteristics of serrated polyp subtypes
Goblet cell HP
SSA with cytological dysplasia
Superimposed dysplasia of conventional intestinal type
Upper crypt serration
Subtle surface serration
Complex villous architecture
Broad crypt base
Goblet cell mucin
Ectopic crypt formations
Dystrophic goblet cells in crypt base
Eosinophilic cells with pencillate nuclei
Sharp demarcation of the dysplastic component
Predominant molecular alteration
Microsatellite instability or TP53 alteration
With the advent of this new nomenclature, prior terminologies such as ‘serrated adenoma’, ‘variant HP’, or ‘mixed polyp’ should no longer be used. In most cases, pathologists are able to classify serrated polyps in each of these categories. However, there are a few situations whereby a definite histological diagnosis can be difficult to achieve. This can be secondary to an unusual appearance of a polyp that displays features of more than one polyp subtype. In this regard, the 2010 WHO classification definition states that if as few as two or three contiguous crypts demonstrate features of SSA in an otherwise HP-appearing polyp, the polyp should be classified as an SSA. Moreover, if a polyp displays an overall growth pattern of a TSA with ectopic crypt formations, but with a predominance of goblet cells (as opposed to tall eosinophilic cells with pencillate nuclei), the polyp should be classified as TSA. It should be noted that these definition criteria are based on a low level of biological evidence. Confusion also occurs when a polyp with an overall growth pattern of SSA displays cytologic features of TSA. A descriptive report is recommended until a better understanding of these lesions is known. Another common difficult situation arises when the polyp is obliquely sectioned, not showing the crypt bases to be able to distinguish HP from SSA. If deeper sections do not help, a diagnosis of ‘non-dysplastic serrated polyp, unclassified’ is recommended. Finally, it may be impossible for the pathologist to distinguish between piecemeal resection of an SSA with cytological dysplasia and the co-occurrence of separate conventional adenoma and SSA when information on the number of polyps submitted in one specimen bottle is lacking. Communication with the gastroenterologist should resolve this problem.
The issue of interobserver reproducibility among pathologists (including gastrointestinal pathologists) to diagnose SSA has been addressed by several groups, showing poor to moderate kappa values (0.14–0.55 between SSA and other polyps) [26–30]. It is anticipated that an increase in awareness among the pathology community and the release of the 2010 WHO criteria  will result in improvement of the reproducibility of serrated polyp diagnosis .
Molecular features of serrated polyps
MAPK pathway activation
The MAPK signaling pathway is commonly altered in CRC and precursor lesions through oncogenic mutation of either the BRAF or KRAS genes. These mutations are mutually exclusive and demonstrate a striking specificity for serrated polyp subtype [19, 32, 33]. BRAF is mutated with increasing frequency in serrated aberrant crypt foci (62 %) , microvesicular HP (70–76 %) [19, 35], borderline SSA (80 %) , SSA (61–100 %) [19, 36–40], and SSA with cytological dysplasia or invasive cancer (64–100 %) [40, 41], supporting the concept of a histologic continuum. BRAF is uncommonly mutated in goblet cell HP. Rather, KRAS is mutated in approximately 50 % of goblet cell HP but rarely in microvesicular HP or SSA .
MAPK pathway activation is also common in TSA, but the relative proportion of BRAF versus KRAS mutation varies widely in different studies, probably reflecting differences in histological classification or small sample size. BRAF mutation rates in TSA range from 27 to 55 % [25, 42, 43] compared to 29–46 % for KRAS mutation [25, 42]. Refinement of the histological features of TSA will increase the consistency of diagnosis and therefore will clarify the involvement of the MAPK pathway in this uncommon polyp subtype.
CpG island methylator phenotype
The CpG island methylator phenotype (CIMP) describes the coordinate hypermethylation of multiple CpG dinucleotide clusters called CpG islands. These CpG islands often reside in gene promoter regions where aberrant DNA hypermethylation frequently correlates with silencing of the downstream gene. The phenotype targets many hundreds of CpG islands; however, the specific gene promoters involved and whether the associated genes become silenced and play a role in the serrated pathway require further investigation.
In CRC, CIMP is highly correlated with BRAF mutation. Rates of CIMP in serrated polyps vary depending on the marker panel used to identify the phenotype, but usually segregate with BRAF mutation. CIMP has been reported in 47–73 % of microvesicular HP, 70–76 % of SSA, and 80 % of SSA with cytological dysplasia [35, 44], suggesting that high levels of aberrant DNA methylation are established early in the serrated pathway. In fact, specific DNA methylation events have even been detected in histologically normal colorectal mucosa and this correlated with the presence of serrated polyps elsewhere in the bowel . CIMP has been less well studied in TSA, but may occur in up to 79 % of cases . TSA with a KRAS mutation may have lower rates of CIMP compared to those with a BRAF mutation, but this requires further investigation.
Other than specific CIMP panel markers, many hundreds of other gene promoters become hypermethylated in serrated polyps as part of this phenotype. Dhir et al.  recently showed accumulation of methylation events with progression of serrated lesions. An average methylation score was determined on the basis of 17 non-CIMP gene promoters which increased from HP to SSA, with highest scores in SSA with cytological dysplasia. The MLH1, CDX2, and TLR2 genes were specifically methylated in SSA and SSA with cytological dysplasia, but not in HP or conventional adenomas. MLH1 silencing is important for progression of a proportion of serrated polyps to cancers showing microsatellite instability. The p16 gene is a cell cycle inhibitor. Methylation-induced silencing of p16 allows escape from BRAF-induced senescence and also occurs with increasing frequency with neoplastic progression .
Wnt signaling pathway
The Wnt signaling pathway plays an important role in the initiation of conventional adenomas, usually through mutation and deletion of the APC tumor suppressor gene. A potential role in the progression of serrated polyps is more controversial. Wnt is a ligand that binds frizzled receptors on the cell membrane, which then signals to stabilize the APC–Axin–GSK3β degradation complex. When APC is silenced, the transcription factor β-catenin is no longer degraded by this complex, but rather accumulates in the cell nucleus, complexing with Tcf/lef to activate transcription of downstream targets that promote oncogenesis. Immunohistochemistry for β-catenin can be used to indicate alteration of Wnt signaling. The normal staining pattern in colonocytes is membranous, compared to nuclear when β-catenin is abnormally stabilized. Altered immunostaining is seen with increasing frequency with serrated polyp progression, although wide variability has been reported [40, 41, 48–56]. Interpretation of staining pattern including the proportion of cells involved and robust experimental methodology are critical to understanding the role of Wnt signaling in serrated polyps.
The Wnt signal may also be altered by genetic or epigenetic targeting of other genes in the signaling pathway. Integration of whole exome mutation and whole genome copy number and gene expression data suggested over 90 % of BRAF mutant tumors have altered Wnt signal, supporting a critical role in serrated as well as conventional neoplasia . The role of Wnt signaling in serrated polyps may be further explored by examining genes in the pathway that may be silenced by DNA hypermethylation. For example, the Wnt pathway antagonists SFRP (types 1–5) are commonly methylated in SSA and SSA with dysplasia, but not in HP . CDX2 is a transcription factor involved in epithelial cell proliferation and differentiation that inhibits the Wnt signal by binding β-catenin and disrupting the β-catenin–TCF complex . The CDX2 gene promoter is methylated in SSA but not in HP or conventional adenomas . MCC is another Wnt pathway molecule that directly interacts with β-catenin to dampen the Wnt signal and this is also methylated in HP and SSA but uncommonly in conventional adenomas .
p53 pathway alterations
The p53 tumor suppressor regulates cellular response to stress through the cell cycle and apoptosis. Aberrant nuclear accumulation of p53, which is suggestive of gene mutation, correlates with dysplastic changes in a proportion of SSAs and TSAs [41, 42]. Although no aberrant staining was observed in 66 HPs or 53 SSAs, 6/12 SSAs with a focus of dysplasia or cancer showed nuclear p53 accumulation . Furthermore, in these and another series of 6/24 TSAs showing aberrant staining, p53 accumulation was limited to the dysplastic cells [41, 42]. Mutation of p53 is uncommon in the serrated neoplasia pathway cancers showing BRAF mutation, CIMP, and microsatellite instability, but is commonly mutated in the 50 % of BRAF mutant, CIMP-positive cancers that do not methylate MLH1 and are therefore microsatellite stable. It is possible that MLH1 methylation and p53 mutation are critical alterations leading to neoplastic change and transition to either microsatellite unstable or microsatellite stable CRC, respectively. IGFBP7 functions downstream of p53 to mediate its tumor suppressor function . In serrated polyps that do not mutate p53, methylation of IGFBP7 may be an alternate mechanism for inactivating the p53 pathway. Interestingly, Kaji et al.  recently suggested that whilst MLH1 and IGFBP7 methylation may often coexist in serrated polyps, the order of events might be important for directing the neoplastic pathway. They hypothesized that primary methylation of IGFBP7 would result in TSA-like histology compared to SSA-like histology when MLH1 is methylated first.
Endoscopic features of sessile serrated adenomas (data from Tadepalli et al. )
Interobserver agreement (κ)
Rim of debris/bubbles
Obscures blood vessels
Alters fold contour
Colonoscopy is not a perfect test, and multiple factors contribute to the variable effectiveness of colonoscopy and its possible limitations for lesion detection. These include patient, technical, health system, and endoscopist factors, such as adequacy of bowel preparation, equipment or reimbursement incentives, and variation in the motivation, visuoperceptual capacity, and skills of the endoscopist [71, 72].
In particular, colonoscopy is less effective at preventing CRC in the proximal compared with the distal colon [73–78]. It is hypothesized that this in part relates to failures to detect, recognize, and completely resect SSA [79, 80]. Consistent with this hypothesis are data showing that cancers occurring after colonoscopy are more likely to be MSI-high and CIMP-high [81, 82], suggesting that they originated in unrecognized SSAs and that exposure to colonoscopy is associated with a lower risk of metachronous advanced conventional adenomas in both the proximal and distal colon, but not SSAs .
Failures in detection and recognition of SSAs therefore pose a major limitation of colonoscopy for CRC prevention. In fact, variation in the detection of serrated polyps between endoscopists is more substantial than the variation in endoscopist detection of conventional adenomas [83, 84]. Two studies now indicate the extent of this variation and suggest that miss rates for serrated polyps are far higher than for conventional adenomas. Specifically, Hetzel et al.  analyzed 4,335 polyps from 7,192 average-risk screening colonoscopies and found that proximal colon SSA prevalence varied between endoscopists from 0 to 1.4 %. The prevalence of SSAs also increased over time, from 0.2 % in 2006 to 1.1 % in 2008. Likewise, Kahi et al.  found in 6,681 colonoscopies that proximal serrated polyp prevalence (per colonoscopy) ranged between endoscopists from 1 to 26 %. As noted earlier, this variation has implications for understanding the true prevalence of SSA at colonoscopy.
Detection of serrated lesions is clearly operator-dependent, indicating that specific knowledge and skills are required for their detection and recognition. Lesion recognition requires “target familiarity” with their characteristic appearance, enabling the examiner to visually distinguish the lesion from the background normal mucosa . It is likely that this requires extensive exposure to serrated lesion appearances  and repeated, deliberate clinical practice.
The role of specific colonoscopic technologies for improving the detection of serrated lesions is unclear. Studies of technologies to improve mucosal exposure at colonoscopy (e.g., cap-fitted colonoscopy , proximal colon retroflexion , and to improve recognition of subtle lesions, e.g., high definition colonoscopy , electronic image-enhancement , dyespray chromoendoscopy ) have not been specifically performed for serrated lesion targets . In the largest study of pancolonic chromocolonoscopy with indigocarmine dyespray, Pohl et al.  found a significant increase in serrated lesion detection (1.19 vs. 0.49 per patient). It is likely that any beneficial impact of these technologies on serrated polyp detection will be greater for those endoscopists with lower baseline levels of polyp detection.
Management of patients with serrated polyps
Consensus recommendations are that all serrated lesions should be removed at colonoscopy, except for diminutive rectosigmoid hyperplastic polyps, which should be randomly sampled for histology [68, 92]. Optimal resection techniques are yet to be defined for serrated lesions, although specific challenges relate to their morphology and indistinct margins . Cold snaring techniques (without electrocautery) are generally recommended for lesions under 10 mm [68, 94]. For larger lesions, electrocautery with or without submucosal injection is warranted. Image-enhancement techniques including NBI, topical dyespray application, or submucosal dye injection (e.g., indigocarmine) may assist in delineating the margin of the lesion. Early colonoscopic follow-up (at 3–6 months) is warranted for piecemeal resection of larger serrated lesions given the specific risks of incomplete resection with these lesions  and reports of early interval cancer .
Summary of studies reporting the mean size of sessile serrated adenoma with and without associated malignant component
Another study looked specifically at the median age of patients with SSAs and found it to be 61 years for SSA, 72 years for SSAs with high-grade dysplasia, and 76 years for patients presenting clinically with cancer related to an SSA . Furthermore, females were over-represented amongst those patients with SSA progressing to high-grade dysplasia and malignancy. Overall, these data suggest that SSA may be present for many years with little change. However, in the cases where invasive malignancy does develop, this happens suddenly without a reliable window of warning signs such as low-grade dysplasia or polyp size greater than 10 mm. This interpretation of the data was also endorsed in recent consensus reviews [68, 92]. It would be very helpful if molecular or clinical markers able to predict which SSAs are most at risk of progression could be developed.
So far there is limited evidence on which to base recommendations for surveillance in patients found to have serrated polyps. In a group of 40 patients who had “hyperplastic polyps” removed between 1980 and 2001 whose polyps were SSAs on review and who were followed up for a mean of 13.2 years, five developed subsequent cancers and one had adenoma with high-grade dysplasia . At the time of the detection of the SSA, these patients had no history of adenomas or cancer and so would not have been recommended to have surveillance according to the guidelines at the time. In another study, 39 patients were identified on colonoscopy between 1994 and 1997 as having proximal non-dysplastic serrated polyps as the only lesion in their bowel and underwent further colonoscopy within 5.5 years . These patients had a 3.14-fold increased risk of adenoma during follow-up compared to control patients with no polyps.
A more recent study reported on 22 patients found to have at least one SSA at colonoscopy in 2005 . Many but not all of these patients had synchronous adenomas or a history of prior polyps. Follow-up colonoscopy over the next 5 years found new SSAs in 11 (50 %) of these patients. Two of the SSAs displayed low-grade dysplasia and one high-grade dysplasia. Adenomas were found in 45 % of patients and one patient developed CRC. Another study published in 2012 reported 43 patients with at least one SSA diagnosed on colonoscopy between 2002 and 2004 with follow-up colonoscopy . At an average of 2.72 years after the initial colonoscopy, SSAs were found in 22 patients (51 %), adenomas in 16 patients (37 %), SSA with high-grade dysplasia in 1 patient, and mucinous carcinoma developed in 1 patient.
Colonoscopy is an excellent tool to prevent CRC but it is costly, invasive, and carries some risk. Thus surveillance colonoscopy in patients known to be at risk aims to be frequent enough to detect lesions prior to malignant transformation but not unnecessarily frequent. To date, most national guidelines for colonoscopy surveillance after polypectomy agree that patients with small, distally located hyperplastic polyps do not require subsequent surveillance [68, 92, 103]. They recognized that other serrated lesions are significant but note that there is limited evidence to make firm recommendations.
Histologic subtype: SSA and TSA are certainly predictive of a higher risk than HPs. It is likely that the presence of low-grade or high-grade cytological dysplasia in a SSA or TSA further heightens the risk of subsequent significant lesions.
Number of polyps: Almost certainly the risk of subsequent polyps and cancer increases with the number of polyps and the most extreme example of this is serrated polyposis where it is agreed that the surveillance interval should be 1 year .
Concomitant conventional adenomas: There is no direct evidence but it is likely that patients with a higher polyp burden due to the presence of both adenomas and serrated polyps are at greater risk.
Location in the colon: Most cancers arising in serrated polyps do so in the proximal colon. However most SSAs are themselves in the proximal colon and it is not certain whether the uncommon SSAs occurring in the distal colon are individually of less risk.
Size of polyps: It is likely that there is an increased risk in patients with larger SSAs but it is not clear that the cutoff of 10 mm used to define advanced conventional adenomas applies to SSAs. SSAs rarely grow larger than 20 mm  and most large polyps are adenomas. As discussed above, the average size of SSAs shown to contain invasive malignancy ranged from 8 to 11 mm.
Current guidelines for colonoscopy surveillance after diagnosis of serrated polyps
Surveillance interval (years)
Proximal to sigmoid
Proximal to sigmoid
Proximal to sigmoid
SSA or TSA
SSA or TSA
SSA or TSA
SSA or TSA
1–3 (serrated polyposis if 3 additional serrated lesions of any size proximal to the sigmoid)
SSA with dysplasia
Conclusions and perspectives
Serrated polyps comprise a diverse group of polyps with common morphological serrated appearance and distinct endoscopic, histological, and molecular profiles. There is growing evidence that interval CRCs in the proximal colon are caused by serrated polyps missed at colonoscopy. This represents a challenge for gastroenterologists to improve the detection rate of sessile polyps, many of which will be SSAs, by increased awareness and the use of advanced imaging techniques. Likewise pathologists should become more familiar with the histological features that distinguish SSA from HP and should use the WHO criteria to correctly diagnose serrated polyp subtypes. Because interobserver variability in histological diagnosis still exists, many experts consider that all serrated polyps in the proximal colon larger than 10 mm in size are likely to be SSAs, even if pathologists interpret them as HPs. The rarer lesion of TSA is still poorly understood and requires additional studies to refine criteria for diagnosis and understanding of the molecular heterogeneity of this polyp subtype. TSAs with KRAS mutation may have different malignant potential than TSAs with BRAF mutation. The recent availability of an antibody that reliably detects BRAF mutation by immunohistochemistry may help in identifying serrated polyps and move towards a more molecularly based classification of colorectal polyps . Detection of BRAF mutation may be particularly helpful in distinguishing SSA with extensive cytological dysplasia from conventional adenoma as these two polyps are likely to have different malignant potential. Serrated polyposis may be more prevalent than initially thought now that gastroenterologists and pathologists have become more aware of this condition. However, prospective studies are needed to assess the risk of CRC and metachronous polyps in patients diagnosed with serrated polyps and serrated polyposis. Until then, the colonoscopy surveillance guidelines are based only on a low level of evidence.
Conflict of interest
The authors declare that they have no conflict of interest.